Glogen Clinical Research Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 06-06-2024
- Paid Up Capital ₹ 4.23 Cr
as on 06-06-2024
- Company Age 13 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2023)
- Profit -90.77%
(FY 2023)
- Ebitda -393.33%
(FY 2023)
- Net Worth -732.43%
(FY 2023)
- Total Assets -8.74%
(FY 2023)
About Glogen Clinical Research
The Company is engaged in the Travel And Hospitality Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 4.23 Cr, as per Ministry of Corporate Affairs (MCA) records.
Rambabu Maddela and Vaishwitha Maddela serve as directors at the Company.
- CIN/LLPIN
U24100AP2011PTC076064
- Company No.
076064
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Aug 2011
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Guntur, Andhra Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Glogen Clinical Research Private Limited offer?
Glogen Clinical Research Private Limited offers a wide range of products and services, including Product Development Research, Toxicology Research, IT Solutions, Research and Development (R&D) Work.
Who are the key members and board of directors at Glogen Clinical Research?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rambabu Maddela  | Director | 14-Jun-2023 | Current |
| Vaishwitha Maddela | Director | 14-Jun-2023 | Current |
Financial Performance of Glogen Clinical Research.
Glogen Clinical Research Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 90.77% decrease in profit. The company's net worth observed a substantial decline by a decrease of 732.43%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Glogen Clinical Research?
In 2023, Glogen Clinical Research had a public holding of 42.15%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Glogen Clinical Research?
Unlock and access historical data on people associated with Glogen Clinical Research, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Glogen Clinical Research, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Glogen Clinical Research's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
